
|Articles|October 7, 2010
Highlights of dry eye Phase 2 clinical study revealed
ISTA Pharmaceuticals has highlighted results from its Phase 2 clinical study on Remura dry eye solution.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Celltrion’s EYLEA-referencing biosimilar, EYDENZELT, receives Canadian approval
2
From skepticism to clarity and focus: A family’s PRESBYOND experience
3
Patent granted to Kiora Pharmaceuticals' KIO-100 formulations
4
How Digital Workflow Boosted my Confidence and Elevated Premium Patient Rates in Cataract Surgery
5















































